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Abstract
Background: The contribution of neuroinflammation and specifically brain lymphocyte invasion is increasingly recognised
as a substantial pathophysiological mechanism after stroke. FTY720 is a potent treatment for primary neuroinflammatory
diseases by inhibiting lymphocyte circulation and brain immigration. Previous studies using transient focal ischemia models
showed a protective effect of FTY720 but did only partially characterize the involved pathways. We tested the
neuroprotective properties of FTY720 in permanent and transient cortical ischemia and analyzed the underlying
neuroimmunological mechanisms.
Methodology/Principal Findings: FTY720 treatment resulted in substantial reduction of circulating lymphocytes while
blood monocyte counts were significantly increased. The number of histologically and flow cytometrically analyzed brain
invading T- and B lymphocytes was significantly reduced in FTY720 treated mice. However, despite testing a variety of
treatment protocols, infarct volume and behavioural dysfunction were not reduced 7d after permanent occlusion of the
distal middle cerebral artery (MCAO). Additionally, we did not measure a significant reduction in infarct volume at 24h after
60 min filament-induced MCAO, and did not see differences in brain edema between PBS and FTY720 treatment. Analysis of
brain cytokine expression revealed complex effects of FTY720 on postischemic neuroinflammation comprising a substantial
reduction of delayed proinflammatory cytokine expression at 3d but an early increase of IL-1b and IFN-c at 24 h after MCAO.
Also, serum cytokine levels of IL-6 and TNF-a were increased in FTY720 treated animals compared to controls.
Conclusions/Significance: In the present study we were able to detect a reduction of lymphocyte brain invasion by FTY720
but could not achieve a significant reduction of infarct volumes and behavioural dysfunction. This lack of neuroprotection
despite effective lymphopenia might be attributed to a divergent impact of FTY720 on cytokine expression and possible
activation of innate immune cells after brain ischemia.
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Introduction
Ischemic stroke is a major cause of death and disability
worldwide. Currently, the only approved therapy for acute stroke
is rapid vascular recanalization which restores the supply of blood
to ischemic tissue [1]. Beyond a shortage of essential metabolites,
ischemia triggers many other detrimental cascades. In particular,
inflammatory mechanisms have come into the focus of research
because they contribute substantially to secondary brain damage
[2,3] and their prolonged kinetics makes them amenable to
therapeutic intervention [4,5]. Recent experimental studies suggest
a pivotal role of T cells in post-ischemic inflammation of various
organs including the brain [6,7,8,9,10]. Although T lymphocytes
are now known to patrol the CNS, the presence and activity of
systemic immune cells in the healthy brain remains very restricted
and tightly controlled by the intact blood-brain-barrier [11].
Cerebral invasion by inflammatory cells is a hallmark in the
pathogenesis of neuroinflammation and contributes substantially
to secondary tissue loss in acute stroke [12,13,14]. Similar to
primary inflammatory CNS disease, deleterious T cell effector
mechanisms in the ischemic brain include proinflammatory
cytokines and potentially direct cytotoxicity [15,16]. Consequent-
ly, preventing the CNS invasion of lymphocytes after brain
ischemia may be a potent strategy for stroke therapy.
Fingolimod (FTY720) has emerged over the last few years as a
potent treatment for clinical multiple sclerosis [17,18,19]. FTY720
is rapidly phosphorylated after administration and resemles
thereby the structure of sphingosine-1-phosphate (S1P). Phosphor-
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the emigration of extravascular leukocytes from tissues [20]. By
functionally antagonizing the S1P receptors, FTY can modulate
the migration of leukocytes. In previous studies in primary
neuroinflammatory disease models, FTY720 effectively inhibited
lymphocyte immigration into the CNS, dampened the humoral
immune respone, and improved the functional outcome after
experimental autoimmune encephalomylitis [21,22,23,24].
Recently, the effectiveness of FTY720 was also tested in murine
models of ischemic brain injury [25,26,27,28]. These studies
showed a beneficial effect of FTY720 on stroke outcome in a
model of transient ischemia in mice [25,26,28] and rats [27].
However, the majority of reports studied the effect on infarct
volume only at early time points (24 h to 4d after MCAO) when
the postischemic invasion of lymphocytes, the key targets of
FTY720, has just begun. Indeed, the mechanisms underlying the
protective effects of FTY were only partially characterized.
Surprisingly, none of the previous studies which were suggesting
a neuroprotective role of FTY720 in stroke has analyzed the
number of invading lymphocytes into the brain after stroke.
Finally, all three studies used a experimental ischemia model that
induced extensive lesions of approx. 50% of the hemisphere – a
model which is known to be associated with high mortality,
induces substantial changes in the systemic immune system and
reflects only a small proportion of clinical strokes in patients
[29,30].
We therefore re-investigated the impact of FTY720 on stroke
outcome in two experimental mouse models inducing moderate
cortical lesions or extensive lesions and analyzed the modulation of
neuroinflammatory effector mechanisms after brain ischemia.
Results
FTY720 reduces the number of circulating leukocytes
We analyzed the cell number of leukocytes and lymphocyte
subsets in blood and immunological organs to verify the putative
lymphocyte arrest in secondary lymphatic organs by FTY720
treatment. Differential blood cell counts after daily administration
(1 mg/kg body weight per day) of FTY720 by oral gavage
revealed a substantial reduction of circulating leukocytes (Fig. 1A).
This effect was mainly due to the decrease in the lymphocyte
population by .80% as early as 6 h after the first dose of FTY720.
Lymphocyte counts remained significantly reduced up to 7d of
FTY720 treatment. The number of circulating granulocytes was
unchanged after FTY720 treatment whereas the initially very low
number of circulating monocytes was increased about 3-fold
already 6 h after FTY720 treatment (before: 2206110 cells/ml,
6 h: 7306230 cells/ml).
Further analysis of lymphocyte subpopulations revealed that
mainly CD4+ T cells were reduced in blood after FTY720
treatment, while other lymphocytes remained largely unaffected
(Fig. 1B and Table 1). Similar to the pattern found in blood, a
significant reduction of T cells and also B220+ B cells was found in
spleens after FTY720 administration (Fig. 1B and Table 1). In
contrast, the number of lymphocytes in mesenteric lymph nodes
was not significantly affected at any time point after FTY720
treatment while CD11b cells were significantly reduced at 6 h and
24 h after FTY720 administration (Fig. 1B and Table 1).
FTY720 treatment does not improve outcome after
experimental ischemic stroke
Previous studies [25,26,27] have shown a neuroprotective effect
of FTY720 on stroke outcome in reversible middle cerebral artery
occlusion (MCAO) models. We analyzed the effect of daily
FTY720 treatment on infarct volume and behavioural dysfunction
after permanent coagulation of the MCA distal of the lenticulos-
triatal arteries. This permanent ischemia model induces moder-
ately sized cortical infarct lesions. We analyzed infarct volumes in
mice receiving daily administrations of 1 mg/kg FTY720 by oral
gavage compared to PBS treated control animals in a pre-
treatment protocol starting 48 h before MCAO and in a post-
treatment protocol starting the treatment 3 h after MCAO. We
Figure 1. FTY720 treatment induces leukopenia. (A) Differential
blood cell counting was performed in normal mice (Naive) and 6 h,
24 h, 3d and 7d after daily administration of FTY720. Mean values (n=5
per time point) are depicted for total leukocytes, granulocytes,
lymphocytes and monocytes as cells per ml whole blood. (B) Leukocyte
subpopulations were further characterized by specific epitope markers
for T cells (CD3, CD4, CD8), B cells (B220), regulatory T cells (Foxp3) and
monocytes (CD11b) at the indicated time points in blood, spleen and
mesenteric lymph nodes (n=5 per group). Each experiment was
performed 2–3 times.
doi:10.1371/journal.pone.0021312.g001
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after MCAO in the pre-treatment protocol starting 48 h before
MCAO (Fig. 2A,B). Infarct volumes were also not significantly
reduced at 7d after MCAO in animals receiving FTY720 by the
post-treatment protocol starting 3 h after MCAO (Fig. 2C). We
additionally analyzed the effect of a single injection of FTY720 to
exclude the possibility of cumulative dose toxicity by the daily
treatment, but did also not measure a significant reduction in
infarct volume at 7d after MCAO in animals that were treated
with a single dose of FTY720 or PBS at 48 h before MCAO.
Moreover, we tested the postischemic sensorimotor function by the
‘‘Corner test’’ [31] and the ‘‘forelimb use asymmetry test’’ [32]
which both correlated well with the infarct volume within the first
week after MCAO in a previous study [13]. We did not detect a
significant reduction of behavioural dysfunction by FTY720
compared to controls at any measured time point after MCAO
in both tests (Fig. 2E,F).
To test the hypothesis of a differential effect of per os FTY720
treatment in an infarct model of ischemia-reperfusion injury of the
brain in contrast to permanent MCA occlusion, we analyzed
infarct volumes 24 h after MCAO in 48 h-pretreated animals
undergoing 60 min reversible occlusion of the MCA (Fig. 3B).
We did not detect a significant effect of FTY720 treatment
compared to PBS on the resulting infarct volume. Additionally, we
tested whether intraperitoneal (i.p.) administration of FTY720
would have a neuroprotective effect in contrast to administration
by oral gavage. Neither in at 7d after MCAO in the coagulation
model (Fig. 3C) nor at 24 h after MCAO in the 60 min filament-
occlusion model (Fig. 3D) a significant difference between
FTY720 and PBS treated animals was detected. Furthermore we
analyzed brain edema formation as a marker of blood-brain-
barrier dysfunction in normal animals receiving FTY720 or PBS
and in mice at 3d after MCAO in both treatment groups (Fig. 4A).
We detected a significant increase in brain water content of the
ischemic hemisphere at 3d after MCAO compared to brains 3d
after Sham operation, but we did not measure a difference
between edema in PBS treated and FTY720 treated animals
(Fig. 4A). Additionally, blood-brain-barrier permeability was
analyzed by measuring Evans blue fluorescence intensity in brain
homogenates at 3d after permanent MCAO in FTY720 treated
mice and controls. We did not measure a significant difference in
the ratio of ischemic/non-ischemic hemispheres for the Evans blue
fluorescence intensity (Fig. 4B).
Physiological cardiovascular parameters are not affected
by FTY720 treatment
We investigated the effect of FTY720 on basal physiological
parameters to exclude major cardiovascular side effects of the
treatment. Therefore, we continuously measured mean intra-
arterial pressure (MAP) after catherization of the femoral artery
(Fig. 5A) and relative cerebral blood flow by laser doppler analysis
(Fig. 5B) for 10 min before and 180 min after oral FTY720
administration. We did not detect a significant alteration of those
parameters between treatment groups.
FTY720 treatment decreases cerebral lymphocyte
invasion
We performed histological analysis for the invasion of systemic
leukocytes and for activation of resident microglial cells to test the
effect of FTY720 on cellular inflammation after experimental
brain ischemia (Fig. 6). We stained histological sections at 5d after
MCAO in FTY720 treated mice (1 mg/kg, daily treatment,
starting 48 h prior to MCAO) and control animals for the
expression of CD3 (T cells), B220 (B cells), MPO (granulocytes)
and IBA1 (microglia/macrophages) (Fig. 6A). FTY720 treatment
significantly reduced cerebral invasion of T cells and B cells
compared to control animals (Fig. 6B). However, MPO-positive
cells (i.e. mainly neutrophil granulocytes) did not significantly
Table 1. Mean values and standard deviations of data shown in Figure 1b.
CD3 CD4 CD8 Foxp3 B220 CD11b
Blood
Naı ¨ve 1,2136165 9026117 311677 84625 6516181 582686
6 h * 557698 * 419651 * 138653 62629 * 430691 4696302
24 h * 5466123 * 3476216 2006166 62627 5106210 4496180
3d * 182641 * 182641 * 54614 * 35626 4166219 * 2886140
7d * 97628 * 3569* 6 8 617 * 42616 5376175 * 312691
Spleen
Naı ¨ve 39.468.4 24.367.7 15.366.1 4.262.0 57.7614.4 6.961.8
6 h * 19.665.8 * 11.463.5 * 8.262.5 * 1.860.5 * 21.865.1 * 1.160.3
24 h * 15.966.0 * 12.864.6 * 5.962.2 * 2.160.5 * 22.466.4 * 1.260.2
3d * 14.566.7 * 11.566.7 * 3.161.3 * 1.560.8 * 31.066.3 * 2.861.0
7d * 2369 * 12.164.9 * 9.062.3 3.260.7 * 27.165.3 4.861.6
Lymph node
Naı ¨ve 8.662.9 5.161.7 3.560.8 0.760.2 4.361.5 0.560.2
6h 5 . 6 61.6 3.361.2 2.360.9 0.460.3 4.061.7 * 0.260.06
24 h 5.860.9 3.660.7 2.260.7 0.760.2 3.560.8 * 0.160.02
3d 6.161.5 4.160.9 2.160.7 0.760.1 5.461.3 0.360.3
7d 7.361.5 5.061.2 3.261.4 1.560.4 4.661.0 0.360.2
*=p,0.05 between Naı ¨ve mice and respective time point after FTY720 (n=5 per group).
doi:10.1371/journal.pone.0021312.t001
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FTY720 treated group had substantially increased MPO+ cell
counts (Fig. 6B). No significant difference was detectable for the
expression of IBA+ cells in brain sections of FTY720 or PBS
treated animals, a marker for activated microglia/macrophages
[33]. We additionally performed flow cytometric analysis of
immune cell subpopulations isolated from brains of PBS- or
FTY720-treated animals 5d after MCAO to confirm histological
data (Table 2) by a previously reported FACS gating strategy
[34]. Correspondingly, we observed a substantial reduction of
brain invading T-helper (CD3+/CD4+) and T-effector (CD3+/
CD8+) cells in FTY720 treated animals compared to controls.
Absolute cell counts per ischemic hemisphere were not signifi-
cantly different for Granulocytes (CD45+/Gr-1+), NK cells
(CD45+/NK1.1+) and for antigen-presenting cells (CD11b+/
MHC-II+) between the treatment groups (Table 2).
FTY720 alters cerebral cytokine expression
To further address the influence of FTY720 on post-ischemic
neuroinflammation, we measured cerebral cytokine expression in
ischemic and non-ischemic hemispheres at 24 h and 3d after
MCAO in PBS and FTY720 treated animals (1 mg/kg, daily p.o.
treatment, starting 48 h prior to MCAO). We analyzed the
expression of the proinflammatory cytokines TNF-a, IL-1b, IFN-c
and IL-6 (Fig. 7A-D) as well as the anti-inflammatory cytokines
IL-10 and TGF-b (Fig. 7E,F). At 3d after MCAO we detected a
significant reduction of all measured cytokines in FTY720 treated
animals compared to control mice except for IL-1b. Interestingly,
Figure 2. FTY720 does not reduce infarct volume after cortical permanent ischemia. Animals in the treatment groups (FTY720) received
daily administrations of 1 mg/kg FTY720 by oral gavage starting at 48 h before infarct induction.I Infarct volumes were determined (A)a t3 d( n=8
per group, p=0.73, 2 individual experiments) and (B) at 7d (n=17, 0.54, 4 individual experiments) after infarct induction. Control animals received
daily PBS injections. (C) Animals were treated daily with either FTY720 or PBS, starting from 3 h after MCAO and infarct volumes were determined at
7d after brain ischemia (n=10, p=0.43, 2 individual experiments). (D) Mice received a single dose of FTY720 or PBS at 48 h before brain ischemia and
infarct volumetry was performed at day 7 (n=10, p=0.27). Behavioural dysfunction and recovery after experimental stroke was assessed in FTY720
pretreated animals (daily treatment starting 48 h before MCAO) or in control animals by the (E) ‘‘cylinder test’’ (n=12, 3 individual experiments) and
the (F) ‘‘corner test’’ (n=12, 3 individual experiments).
doi:10.1371/journal.pone.0021312.g002
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with a significant increase in the expression of IL-1b (Fig. 7B) and
IFN-c (Fig. 7D) in the FTY720 group compared to control
animals [13,29].
FTY720 differentially affects systemic cytokine secretion
We also analyzed serum cytokine levels in naı ¨ve animals and at
24 h and 5d after MCAO in PBS- and FTY720-treated animals to
control for systemic humoral alterations. We measured cytokine
concentrations of the pro-inflammatory cytokines IL-6, IFN-c and
TNF-a (Fig. 8A-C) as well as the anti-inflammatory cytokines
TGF-b and IL-10 (Fig. 8D,E). Interestingly, we detected a
significant increase of serum concentrations of IL-6 and TNF-a in
naı ¨ve animals after FTY720 treatment compared to control
animals (Fig. 8A,C). At 24 h after MCAO we also measured an
increase of IL-6 levels (Fig. 8A) but a reduction of IFN-c
concentrations in FTY720 treated animals (Fig. 8B). Cytokine
levels of the anti-inflammatory cytokines TGF-b and IL-10 were
not altered by the treatment (Fig. 8D,E). Taken together, these
results might indicate a partial early activation of the systemic
immune system by FTY720 administration.
Discussion
This preclinical study was conducted to evaluate the potential of
FTY720 for the treatment of ischemic stroke. The main findings of
this study are that 1) FTY720 reduces postischemic cerebral
lymphocyte influx but 2) does not improve outcome after focal
ischemic stroke after permanent focal ischemia 3) FTY treatment
had complex and partially opposite effects on cerebral and
systemic inflammatory markers which may explain the lack of
efficacy on outcome after experimental stroke.
Previous studies analyzed infarct outcome 24 h or 4d after
stroke in mice and up to 3d after brain ischemia in rats,
respectively [25,26,27]. Interestingly, the protective effects in these
studies are unlikely to have been caused by prevention of
postischemic brain invasion of lymphocytes – the main mechanism
of action of FTY720 in multiple sclerosis and experimental
autoimmune encephalitis [18,20,22,35]. Invasion of leukocytes
into the brain takes place in a distinct kinetic order for each
subpopulation. While the invasion of monocytes/macrophages
and granulocytes can take place within hours after brain ischemia,
relevant numbers of lymphocytes begin to invade the brain only 3–
5 days after experimental stroke [13,25,36,37,38]. Therefore,
other mechanisms than inhibition of brain lymphocyte influx
would be needed to explain the observed effects. In a recent report
by Wei and coworkers a prolonged beneficial effect of FTY720 up
to 14d after ischemia was shown [28]. Interestingly, FTY
improved the behavioural dysfunction while infarct volume,
neuronal apoptosis and inflammatory markers were not affected
and cerebral lymphocyte immigration was not examined. As in
vitro experiments did not support anti-apoptic effects on neurons,
the mechanisms underlying the protective action of FTY720 in vivo
remained unclear [28].
All of the previous studies investigating the effect of FTY720 on
infarct outcome used an experimental stroke model that differs
from the model used for the majority of experiments in the present
study [25,26,27,28]. In contrast to the permanent ischemia model
used in our study, these models comprise a proximal transient
occlusion of the MCA which causes extensive lesions and a high
Figure 3. FTY720 does not alter infarct volume in alternative experimental protocols. (A) Representative images of brain sections stained
by the silver-staining technique from coagulation-MCAO and transient 60 min filament-MCAO as used for determination of infarct volumes. (B) Brain
ischemia was induced by 60 min reversible MCAO and infarct volumes were determined at 24 h after ischemia in animals receiving daily oral
administration of FTY720 or PBS starting 48 h before stroke induction (n=12, p=0.42, 3 individual experiments). (C, D) FTY720 or PBS were
administered by daily i.p. injection starting 48 h berfore MCAO. (C) MCAO was induced by transcranial permanent coagulation and infarct columes
determined at 7d after MCAO (n=10, p=0.36, 2 individual experiments). (D) MCAO was induced by transient 60 min filament-occlusion of the MCA
and infarct volume measured at 24 h after MCAO (n=9, p=0.86, 2 individual experiments).
doi:10.1371/journal.pone.0021312.g003
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was performed in a model of permanent occlusion of the distal
MCA, thereby inducing cortical, medium-sized ischemic lesions of
approx. 15% of the ipsilateral hemisphere. This lesion resembles
embolic infarctions in the MCA territory which are observed in a
large portion of patients with ischemic strokes. In contrast to the
cited investigators, we did not see a beneficial effect of FTY720
treatment on infarct volume either 3d or 7d after MCAO.
Furthermore, it did not matter whether the treatment was started
before or after stroke nor whether the drug was given in a single
dose or daily or whether the drug was administered per oral
gavage or intraperitoneally. We also used a model of extensive
focal brain lesions as used in the previous studies and did not
detect a reduction in infarct size at 24 h after brain ischemia,
neither by oral nor intraperitoneal drug administration.
An advantage of the ‘‘MCA coagulation model’’ is that it allows
to study the pathophysiology and potential treatment effects for
prolonged periods after stroke in mice because the mortality rate,
an important potential confounder, is low (,5%). We observed a
substantial reduction of postischemic cerebral lymphocyte influx
by FTY720 compatible with reports in studies of primary
neuroinflammatory diseases [22]. In contrast, microglia/monocyte
counts were not affected by the treatment and granulocyte
invasion was even strongly increased in some animals. This
apparent heterogeneity of the FTY720 effect on the post-ischemic
immune system was also reflected in the expression pattern of
cerebral cytokines. Three days after MCAO, cerebral IFN-c
expression - which is mainly produced by invading lymphocytes at
this time [13] - was attenuated by FTY720. In contrast, we
observed a substantial increase of pro-inflammatory cytokines (e.g
IL-1b) 24 h after MCA which are mainly secreted by invading
monocytes and activated local microglia [39,40] and have
predominantly harmful effects at this stage [16,41,42,43].
The lack of brain protection despite effective inhibition of
lymphocyte transmigration – a therapeutic concept that was
efficacious in several other studies [10,12,13,14,44,45] – may have
alternative explanations. First, in contrast to primary neuroin-
flammatory diseases, the physical integrity of the blood-brain
barrier is severely disturbed after ischemic stroke [46] which may
allow uncontrolled brain entrance and potentially cytotoxic effects
of FTY720. Effects of FTY720 treatment on oligodendrocytes,
astrocytes, oligodendrocyte progenitor cells and neurons have
been investigated in several in vitro studies, documenting the
multiple pathways that are targeted by S1P. Interestingly,
neuronal activation, differentiation and neurite outgrowth and
retraction by FTY720 seems to be differentially affected under
physiological conditions and in an inflammatory milieu that
increases the sensitization for S1P signaling [see [47] for detailed
review]. Secondly, besides affecting the cellular migration of
immune cells, S1P has distinct modulatory functions on their
maturation and activation [48]. For example, S1P can change the
macrophage phenotype from a pro-inflammatory M1 to a IL-10
secreting M2 phenotype [49,50]. Thereby, antagonists of S1P-
receptors such as FTY720 may prevent a downregulation of innate
immune responses after brain ischemia which are commonly
observed [51]. Indeed, we detected an increased production of IL-
1b and downregulation of IL-10 secretion in brains of FTY720
treated animals. Recently, Michaud et al.[52] proposed a novel
mechanism of activation and increased macrophage accumulation
at the site of inflammation by S1P-inhibition, opposing to the
arrest of lymphocyte-egress. This may correspond to the 3-fold
increase of circulating monocytes as early as 6 h after FTY720
administration. Conceivably, FTY720 treatment has on the one
side a potent effect on the migratory capabilities of lymphocytes
that might be beneficial after ischemic stroke. On the other side
the peripheral immune system is substantially altered after acute
brain lesions [29,30,53] and might be especially susceptible to S1P
antagonist-induced paradox effects, like the activation of innate
immune cells.
Additionally, previous studies have shown a function of S1P
receptors in cardiac function [54] and constriction of cerebral
arteries [55]. We therefore investigated the effect of FTY720
treatment on mean arterial pressure and CBF but did not detect
significant alterations of these parameters by the treatment.
In conclusion, our study fails to confirm previous reports of a
protective effect of FTY720 in experimental ischemic stroke.
Besides differences of experimental modeling among studies, our
findings suggest a heterogeneity of immunological effects of
FTY720 including an enhanced activation of innate immune
Figure 4. FTY720 does not influence brain edema and blood-
brain-barrier permeability. (A) Brain water content was analyzed as
the percentage water content per hemisphere by the ‘‘wet/dry weight’’
method and is shown as the water content ratio of ischemic/non-
ischemic hemispheres. Open bars represent water content ratios in
animals at 3d after Sham operation (‘‘Sham’’) and black bars in mice at
3d after permanent coagulation MCAO (‘‘MCAO’’) receiving FTY720 or
PBS treatment by oral gavage (n=5 per group, 2 individual
experiments). (B) Blood-brain-barrier permeability was tested using
the Evans blue assay for dye extravasation at 3d after permanent
coagulation MCAO in mice receiving FTY720 or PBS treatment by oral
gavage. Data is shown as the ratio for ischemic/non-ischemic
hemisphere fluorescence intensity at 680 nm (n=5, one experiment).
doi:10.1371/journal.pone.0021312.g004
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immunomodulatory therapies such as FTY720 as a potential
treatment for ischemic stroke has to take into account the
complexity and context-dependency of the postischemic systemic
and cerebral immune modulation.
Materials and Methods
Animals
The study was conducted in accordance with national
guidelines for the use of experimental animals, and the protocols
were approved by the governmental committees (Regierungsprae-
sidium Karlsruhe, Germany). We used age-matched, mature male
mice (C57BL/6, 8–10 weeks old, Charles River Laboratories).
Animal models
Mice were treated daily by oral gavage (p.o.) with 1 mg/kg
FTY720 in 100 ml PBS starting at 48 h before or at 3 h after
ischemia induction, control animals received PBS. Animals shown
in Fig. 2D were treated p.o. with a single dose of FTY720, mice
shown in Fig.3C/D were treated with daily intraperitoneal (i.p.)
injection of 1 mg/kg FTY720 in 100 ml PBS starting at 48 h
before MCAO.
Coagulation model. We used this model for all experiments
as previously described [56], except for data depicted in Fig. 3B
and 3D. Briefly, mice were anesthetized with 1.0–2.0% halothane
in O2/N2O. After making a 1 cm skin incision between the left
eye and ear, a burr hole was drilled through the temporal skull.
The dura mater was removed and the middle cerebral artery
(MCA) was occluded permanently using a bipolar
electrocoagulation forceps (ERBOTOM, Erbe). For laser
doppler measurements, we placed the probe (P403, Perimed)
3 mm lateral and 1 mm posterior to the bregma and obtained
relative perfusion units (Periflux4001, Perimed). Only animals in
which relative CBF dropped below 25% of preischemic baseline
after MCAO were included in the analysis. During the operation,
body temperature was kept at 37uC using a feedback controlled
heating pad. After suturing the skin lesion, the mice were placed in
a cage under an infrared heating lamp until recovery from
anesthesia. The overall mortality in the coagulation model was less
than 5% during the 7d observation period.
Filament model. We used this model exclusively for
experiments shown in Fig. 3. Mice were anesthetized with 1.0–
2.0% halothane in O2/N2O-enriched air. We placed the laser
doppler probe over the cortical area supplied by the MCA.
Baseline CBF was measured as relative perfusion units and defined
as 100% flow. After neck dissection, we made an incision into the
left external carotid artery (ECA) between two ligations and
advanced a silicon-covered 8-0 nylon monofilament through the
internal carotid artery to occlude the MCA. MCA occlusion was
documented as a decrease in relative perfusion values by laser
doppler to less than 20% of original flow, a less pronounced
decrease in CBF was used as an exclusion criterion. We fixed the
filament in this position by ligation, closed the neck, removed the
doppler probe and placed the mouse in its cage. Then, 60 min
after filament insertion the mouse was reanesthetized and the
filament removed. After we closed the surgical wound, the mice
were transferred to their cages with free access to water and food.
During the operations body temperature was kept at 37uC with a
feedback controlled heating pad. We maintained normal body
temperature between operations and until recovery after the
procedure by an infrared heating lamp.
Figure 5. FTY720 does not affect basal cardiovascular parameters. Mean arterial pressure (A) and cerebral blood flow (B) were recorded for
10 min before and 180 min after oral administration of 1 mg/kg FTY720 in 100 ml PBS or 100 ml PBS alone. Values are expressed as relative units in
relation to baseline values before the respective treatment (n=3 per group, each mouse was an individual experiment).
doi:10.1371/journal.pone.0021312.g005
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doppler probe as described above. Additionally, a catheter was
placed into the left iliac artery through the femoral artery for
consecutive recording of relative cerebral blood flow and arterial
blood pressure before and after treatment with FTY720 (1 mg/kg)
or PBS.
Figure 6. FTY720 decreases cerebral lymphocyte invasion. (A) Brain sections were stained 5d after MCAO for T cells (CD3), B cells (B220),
granulocytes (MPO) and activated microglia/macrophages (IBA1). (B) Analysis of absolute cell counts of T cells, B cells, granulocytes and microglia/
macrophages per total hemisphere in PBS and FTY720 treated animals at 5d after MCAO (n=6–10 per group, 2–3 individual experiments).
doi:10.1371/journal.pone.0021312.g006
Table 2. Flow cytometric analysis of brain immune cells at 5d after permanent MCAO.
CD3/CD4 CD3/CD8 CD45/Gr-1 CD45/NK1.1 CD11b/MHC-II
PBS 506762349 910066930 57333627341 49000643841 17033610866
FTY720 230361842 383361746 54000659397 29000632527 10033611832
p value 0.091 0.039 0.875 0.274 0.326
Cells per one hemisphere (Mean6SD). N=6 mice per group. Data of 2 individual experiments.
doi:10.1371/journal.pone.0021312.t002
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For the ‘‘forelimb use asymmetry test’’ [32], we placed the mice
in a transparent glass cylinder and videotaped them for 3–10 min,
depending on degree of movement. The independent use of the
forelimb was analyzed by a video player with slow motion and
frame-by-frame capabilities (VLC Media Player). To assess
independent use of left or right forelimb we scored (1) contact of
the cylinder wall with one forelimb during a full rear and (2)
landing with only one forelimb at the cylinder bottom after a full
rear. At least 20 independent contacts were counted for one
forelimb and each experiment was performed twice, with a 1 h
break for the mouse between testing. Forelimb use asymmetry was
expressed as a ratio of right and left-sided, independent forelimb
use.
For the ‘‘corner test’’ [31], we placed the mice between two
boards set at a 30u angle and allowed to move freely. We counted
left and right turns with a rearing movement after deep entry in
the corner and calculated the ratio of right and left turns as an
indicator of behavioural asymmetry. At least 12 full turns after a
rearing movement were counted for each testing.
Assessment of infarct volume
We deeply anesthetized the mice and perfused them transcar-
dially with 20 mL normal saline. We removed the brains from the
skull and froze them immediately in isopentane (220uC). We cut
20 mm thickcoronal cryosectionsevery400 mm,stainedthesections
using the high-contrast silver staining protocol [57], scanned them
at 600 dpi, and analyzed the infarct area on each section (Scion
Image). For the permanent coagulation model inducing exclusively
cortical infarcts, the Swanson method [58] was applied for indirect
infarct measurement and correction for cortical swelling: [Ischemic
area] = [Cortex area of the contralateral side] – [Non-ischemic
cortex area of the ipsilateral side]. For the filament model
comprising also subcortical lesions, we used direct infarct measure-
ment and corrected for brain edema by subtracting the ipsilateral
minus contralateral hemisphere area from the directly measured
Figure 7. FTY720 treatment affects post-ischemic cerebral cytokine expression. Cytokine mRNA relative expression (RE, normalized to Ppia
housekeeping gene) for pro-inflammatory (TNF-a, IL-1b, IL-6 and INF-c, A-D) and anti-inflammatory (IL-10 and TGF-b, E,F) cytokines was measured at
24 h and 3d after MCAO by RT-PCR in the ischemic (black bars) and nonischemic (open bars) hemispheres of control (PBS) and FTY720 treated mice
(n=8 per group, 2–3 individual experiments per group). * P,0.05 between ischemic hemispheres of treatment and control groups at one respective
time point.
doi:10.1371/journal.pone.0021312.g007
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measured areas and distances between sections.
Brain edema measurement
Anesthetized mice were sacrificed, the brain was removed and each
hemisphere was weighed using an electronic analytical balance
(Sartorius) to determine the wet weight (WW) [59]. Then, both
hemispheres were dried in an oven at 70uC for48 h and weighed again
to obtain the dry weight (DW). The formula (WW - DW) / WW x 100
was used to calculate the water content of each hemisphere as a
percentage. The data was expressed as the index of the percentage
water content in the ischemic divided by the non-ischemic hemisphere.
Evans blue assay
Blood brain barrier permeability was measured by the Evans
blue method, according to previous reports [60,61]. Mice were
injected i.v. with Evans blue dye and then perfused with PBS 1 h
later, Each hemisphere of brains at 3d after MCAO were
homogenized and fluorescence was measured on a fluorophotom-
eter (Synergy 4, Biotek) at 680 nm. Fluorescence intensity of
ischemic hemispheres was normalized to the values of the
respective non-ischemic hemisphere.
Differential blood cell counting
Blood samples were collected at the respective time points after
treatment by retroorbital puncture and immediately analyzed in
the Core Laboratory Facilities of the University Hospital
Heidelberg for a complete blood cell count.
Flow cytometry
We collected blood samples and secondary immunological
organs at various time points after MCAO for flow cytometric
analysis of leukocyte subpopulations. We used a previously
published protocol for quantitative FACS analysis and respective
gating strategy of leukocyte subpopulations infiltrating the brain
[13,34]. We stained single cell suspensions for anti-mouse CD3
(Clone 17A2), CD4 (Clone RM 4-5), CD25 (Clone 7D4), Foxp3
(Clone FJK-16s), B220 (Clone RA3-6B2), NK1.1 (Clone PK136),
Gr-1 (RB6-8C5), CD11b (Clone M1/70), MHC-II (M5/114.15.2)
and the appropriate isotype control by following the manufactur-
er’s protocols (eBioscience). We performed flow cytometry on a
Becton Dickinson FACS Calibur and analyzed the data by
CellQuest Pro software. Gates were set according to unstained
samples and isotype control; compensation was adjusted using BD
CaliBRITE Beads (BD Bioscience).
Figure 8. FTY720 changes serum cytokine levels. Serum cytokine concentrations of the pro-inflammatory cytokines IL-6, IFN-c and TNF-a (A–C)
and anti-inflammatory cytokines TGF-b and IL-10 (D,E) were measured in naı ¨ve mice and at 24 h and 5d after FTY720 or control treatment. Each assay
was performed in duplicate (n=5, serum sampling as 2–3 individual experiments, assays as one experiment). * P,0.05 between treatment groups at
the respective time point.
doi:10.1371/journal.pone.0021312.g008
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We performed immunohistochemistry of mature T lympho-
cytes, B cells and neutrophilic granulocytes on coronal cryostat
sections (12 mm), taken at the anatomical landmark of the anterior
commissure, after pretreatment with 4% PFA for 60 min. We
blocked endogenous peroxidase by Peroxidase Blocking solution
(Dako), then incubated the sections with primary antibodies
against CD3 (Clone 3H698, Zytomed) or myeloperoxidase (Clone
RP-053; Zytomed) for 60 min at 21uC. Immunoreactivity was
visualized by a universal immunoenzyme polymer method
(Nichirei Biosciences) and sections developed in diaminobenzidine.
We investigated the distribution of activated microglia by
immunohistochemical staining of coronal cryostat brain sections
(12 mm) for IBA1 (Wako). Immunoreactivity was visualized by the
avidin-biotin complex method and sections developed in diami-
nobenzidine. For analysis of cell number, we captured the images
on a Zeiss Axiovert 200 M microscope. Blinded samples were
evaluated for absolute cell counts by 3 individual analyzers (A.L.,
W.Z., H.D.) not informed about treatment groups. One complete
ischemic hemisphere per mouse was analyzed on coronal sections
at the anterior commissure position by consecutive high power
field analysis for the presence of positively stained cells. All images
for the analysis of IBA1+ cell numbers were processed with the
TissueQuest software (TissueGnostics) for cell-based counting of
automatically recognized IBA1 positive cells in a FACS-like
manner of scattergram analysis [13,62]. Nonspecifically stained
structures and objects that were too large were excluded from the
analysis.
RNA isolation and RT-PCR
We isolated RNA from separated cerebral hemispheres with
RNApure (Peqlab) and performed reverse transcription with the
High Capacity cDNA Archive Kit (Applied Biosystems) on an
ABI7500 RT-PCR System (Applied Biosystems). Primers were
purchased as ready-to-use primer sets for each gene (Super Array).
All assays were run in duplicate. We normalized the results for
each individual gene to the level of the housekeeping gene
encoding for peptidylprolyl isomerase A (cyclophilin).
Cytokine enzyme-linked immunosorbent assay
We collected serum by retroorbital puncture and centrifugation
and froze it at 280uC immediately until analysis of cytokine
protein concentrations with commercial kits for the quantitative
assay of INF-c, IL-10 (all from R&D Systems), TGF-b, IL-6 and
TNF-a (eBioscience). Detection limits were 2.0 pg mL-1 for INF-
c, 4.0 pg mL-1 for IL-10, 7.0 pg mL-1 for TGF-b, 4.0 pg mL-1
for IL-6 and 5.1 pg mL-1 for TNF-a.
Statistical analysis
All values in bar graphs are expressed as mean 6 standard
deviation (SD). We analyzed infarct volumes and functional
outcome tests by two-tailed Student’s t test after validating the
normal distribution of these data sets (Kolmogorov-Smirnov test).
For the remaining data, we used two-tailed Wilcoxon rank-sum
test, using GraphPad Prism 5 software. A p,0.05 was considered
statistically significant.
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